TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6131857
Drug: 2 x
Normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 400 mg cimetidine
Study: 23715669
Drug: Colloid administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloid administration
Study: 31067347
Drug: Intervention arm
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention arm (screening with prostate-specific antigen and digital rectal examination)
Study: 19927136
Drug: Pill count
Normalized name: Pill Counting Tray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pill count
Study: 19927136
Drug: Both MEMS
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both MEMS and pill count
Study: 15957843
Drug: Aiyishu Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aiyishu Injection (AYSI), 50 ml by intrathoracic and another 50 ml by intravenous injection, repeated after 3 days.
Study: 15957843
Drug: Chemotherapeutic agent
Normalized name: Other chemotherapeutics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapeutic agent or interleukin-2 (IL-2)
Study: 12048138
Drug: Bezafibrate treatment
Normalized name: bezafibrate
DrugBank: Bezafibrate (DB01393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bezafibrate treatment for 3 months
Study: 7573262
Drug: Pyridoxine hydrochloride,
Normalized name: Pyridoxine Hydrochloride, 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridoxine hydrochloride, 30 mg per day
Study: 2253535
Drug: Cimetidine 300
Normalized name: cimetidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 300 mg four times a day
Study: 29057618
Drug: Bococizumab 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bococizumab 0.25 mg/kg
Study: 29057618
Drug: Bococizumab 1
Normalized name: Brolucizumab
DrugBank: Brolucizumab (DB14864)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bococizumab 1 mg/kg
Study: 29057618
Drug: Bococizumab 3
Normalized name: Brolucizumab
DrugBank: Brolucizumab (DB14864)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bococizumab 3 mg/kg
Study: 29057618
Drug: Bococizumab 6
Normalized name: brolucizumab
DrugBank: Brolucizumab (DB14864)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bococizumab 6 mg/kg
Study: 29057618
Drug: Bococizumab 6
Normalized name: brolucizumab
DrugBank: Brolucizumab (DB14864)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bococizumab 6 mg/kg (all three doses)
Study: 26228480
Drug: Bolstered usual
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolstered usual care plus a family-level economic strengthening intervention (Suubi-Maka treatment arm)
Study: 21292625
Drug: Drug Burden
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug Burden Index (DBI)
Study: 17914954
Drug: Rabeprazole 20
Normalized name: RABEprazole 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 20 mg for 2 days and 1 hour before the test
Study: 11809341
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg tibolone (Livial) daily for 12 months
Study: 10052765
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and root planing + 2% minocycline gel (S+Min)
Study: 10052765
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and root planing + 25% metronidazole gel (S+Met)
Study: 7485940
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of blood salvage and three units of PABT
Study: 7422399
Drug: Phenobarbital (PB)
Normalized name: Phenobarbital
DrugBank: Phenobarbital (DB01174)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbital (PB) 100 mg at bedtime for the last few weeks of pregnancy
Study: 7422399
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no phenobarbital treatment)
Study: 7422399
Drug: Children with
Normalized name: Pediaclear Childrens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children with moderate or marked jaundice (bilirubin > 12 mg/dl)
Study: 31526875
Drug: CR4056 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: CR4056 (100 mg bid for women; 200 mg bid for men)
Study: 26016861
Drug: High egg
Normalized name: EGG
DrugBank: Egg (DB10529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High egg (HE) meal (150 g scrambled whole eggs)
Study: 26016861
Drug: Low egg
Normalized name: EGG
DrugBank: Egg (DB10529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low egg (LE) meal (75 g scrambled whole eggs)
Study: 23958768
Drug: Computerized decision
Normalized name: Precise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerized decision support system for ADHD diagnosis and treatment guidelines.
Study: 15302282
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist + recombinant LH (75 IU/day)
Study: 15302282
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist alone (C)
Study: 11536410
Drug: Velocity-dependent method
Normalized name: Vitamin K-dependent protein S
DrugBank: Protein S human (DB13149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Velocity-dependent method (16-18 mL of gadolinium)
Study: 11536410
Drug: High-dose method
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose method (38 mL of gadolinium)
Study: 9491873
Drug: Oral 17beta-estradiol
Normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral 17beta-estradiol (E2), 1 mg daily, combined sequentially with dydrogesterone 5 or 10 mg (14 days per 28-day treatment cycle) for 12 months, then E2, 2 mg daily, combined with dydrogesterone, 10 mg daily (14 days per 28-day treatment cycle) for 3 months
Study: 3380504
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of meperidine
Study: 30548928
Drug: Multimedia surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimedia surgical care tour (4 educational videos and automated reminders to take medications)
Study: 28545493
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily testing with standard feedback (glucose values reported immediately)
Study: 28545493
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily testing with enhanced patient feedback (glucose values reported immediately plus automated tailored feedback messaging)
Study: 25437509
Drug: Supervised therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised therapy (n=89)
Study: 25437509
Drug: Home-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based therapy (n=36)
Study: 25437509
Drug: Supervised therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised therapy (high performers, n=70)
Study: 25437509
Drug: Home-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based therapy (high performers, n=38)
Study: 25437509
Drug: Supervised therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised therapy and Home-based therapy (WOMAC subscales)
Study: 22789392
Drug: interpositional intra-oral
Normalized name: somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: interpositional intra-oral autogenous bone graft
Study: 19591067
Drug: Oral Naltrexone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Naltrexone (NTX) treatment 3 times per week for 12 weeks
Study: 19591067
Drug: Study medication
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study medication (NTX)
Study: 16406224
Drug: DTPa-IPV booster
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPa-IPV booster vaccine
Study: 15291288
Drug: Cyclic nonplatinum
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic nonplatinum chemotherapy
Study: 11702325
Drug: Propofol (5‐10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (5‐10 mg/kg/h) and remifentanil (0.125‐1.0 microgram/kg/min)
Study: 9389861
Drug: alfentanil 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: alfentanil 20 micrograms kg‐1, propofol 2.5 mg kg‐1 and vecuronium 0.1 mg kg‐1
Study: 9389861
Drug: thiopentone 5
Normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: thiopentone 5 mg kg‐1 and suxamethonium 1 mg kg‐1
Study: 3286173
Drug: PPA 75
Normalized name: Guaifenex PPA 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPA 75 mg SR
Study: 3286173
Drug: PPA SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPA SR 75 mg with caffeine 200 mg
Study: 28707491
Drug: Omega-3 supplement
Normalized name: Systane Vitamin Omega-3 Supplement Softgel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 supplement (1g fish oil)
Study: 21177517
Drug: Acceptance-based behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance-based behavior therapy (ABBT)
Study: 18377622
Drug: Serum enriched
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum enriched in marine compounds
Study: 18377622
Drug: Cream formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream formulation
Study: 18377622
Drug: Lotion and
Normalized name: KIT, LOTION AND CREAM, EMOLLIENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lotion and cream formulations
Study: 18377622
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (after stopping treatment)
Study: 17313803
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 mg/d for 7 days before surgery
Study: 17313803
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of celecoxib 200 mg/d and octreotide 100 microg injected subcutaneously for 7 days before surgery
Study: 17313803
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no anti‐tumor medicine before GC resection)
Study: 12682082
Drug: Eplerenone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone (50 to 200 mg daily)
Study: 12682082
Drug: Amlodipine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (2.5 to 10 mg daily)
Study: 10067694
Drug: Combined, short
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined, short schedule group (Co-S) - DTaP and PRP-T vaccines reconstituted immediately prior to injection at 3, 4 and 5 months of age
Study: 10067694
Drug: Associated, long
Approvals — FDA: no, EMA: no, PMDA: no
Description: Associated, long schedule group (As-L) - DTaP + PRP-T at separate sites at 2, 4 and 6 months
Study: 10067694
Drug: DTwP (whole-cell)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTwP (whole-cell) vaccine
Study: 2378547
Drug: Fluphenazine hydrochloride
Normalized name: Fluphenazine Hydrochloride
DrugBank: Fluphenazine (DB00623)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluphenazine hydrochloride 10 mg daily
Study: 2378547
Drug: Fluphenazine hydrochloride
Normalized name: Fluphenazine Hydrochloride
DrugBank: Fluphenazine (DB00623)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluphenazine hydrochloride 20 mg daily
Study: 2378547
Drug: Fluphenazine hydrochloride
Normalized name: Fluphenazine Hydrochloride
DrugBank: Fluphenazine (DB00623)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluphenazine hydrochloride 30 mg daily
Study: 2378547
Drug: Fluphenazine hydrochloride
Normalized name: Fluphenazine Hydrochloride
DrugBank: Fluphenazine (DB00623)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluphenazine hydrochloride (various doses)
Study: 2378547
Drug: Fluphenazine hydrochloride
Normalized name: Fluphenazine Hydrochloride
DrugBank: Fluphenazine (DB00623)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluphenazine hydrochloride (doses over 0.3 mg/kg per day)
Study: 19025
Drug: Lorazepam 4
Normalized name: lorazepam 4 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam 4 mg/70 kg i.m.
Study: 19025
Drug: Morphine 10
Normalized name: morphine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 10 mg/70 kg i.m.
Study: 15354524
Drug: Alpha1‐adrenoceptor blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha1‐adrenoceptor blocker (Terazosin 2 mg qn) and Levo‐ofloxacin (0.2 bid)
Study: 11571657
Drug: Intracavernous injection
Normalized name: Bivalirudin 250 mg INTRACAVERNOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracavernous injection with prostaglandin E1
Study: 9829447
Drug: Azelaic acid
Normalized name: Azelaic Acid
DrugBank: Azelaic acid (DB00548)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Azelaic acid 20% cream and glycolic acid 15% or 20% lotion
Study: 8008725
Drug: dicloxacillin 500
Normalized name: dicloxacillin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: dicloxacillin 500 mg 3 times a day
Study: 8008725
Drug: dicloxacillin 250
Normalized name: dicloxacillin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: dicloxacillin 250 mg + probenecid 250 mg 3 times a day
Study: 3619135
Drug: Enprofylline 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enprofylline 2.5 mg/kg
Study: 3619135
Drug: Theophylline (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (standard dose)
Study: 22354147
Drug: Antihypertensive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive therapy for 13 months
Study: 11182531
Drug: Lithium treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium treatment (acute administration for 7 days)
Study: 7547043
Drug: 4% amethocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% amethocaine gel
Study: 7963202
Drug: Carbamazepine (modal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine (modal dose 300 mg/day)
Study: 29226809
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (14,000 IU weekly)
Study: 24257813
Drug: CYP450 genotype
Normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYP450 genotype and antidepressant serum concentration
Study: 24257813
Drug: Differences in
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Differences in antidepressant serum concentrations
Study: 21190450
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no cell therapy)
Study: 2444132
Drug: 2.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg/kg propofol (Disoprivan)
Study: 2444132
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg methohexital (Brevimytal)
Study: 2444132
Drug: 1.4 microgram
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.4 microgram fentanyl + 0.07 mg/kg droperidol (Thalamonal)
Study: 27453037
Drug: 500 mL
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mL isotonic drink
Study: 27453037
Drug: 500 mL
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mL water
Study: 23678501
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of implementation intentions and self-efficacy (II+SE) group
Study: 18721244
Drug: Entecavir 1
Normalized name: entecavir 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entecavir 1 mg/day
Study: 12131216
Drug: HIVIGLOB 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIVIGLOB 50 mg/kg
Study: 12131216
Drug: HIVIGLOB 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIVIGLOB 200 mg/kg
Study: 12131216
Drug: HIVIGLOB 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIVIGLOB 400 mg/kg
Study: 7673302
Drug: Collagenase ointment
Normalized name: collagenase Topical Ointment
DrugBank: Collagenase clostridium histolyticum (DB00048)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Collagenase ointment with polymyxin B sulfate/bacitracin powder
Study: 7673302
Drug: Silver sulfadiazine
Normalized name: Silver Sulfadiazine
DrugBank: Silver sulfadiazine (DB05245)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silver sulfadiazine cream (1%)
Study: 1981681
Drug: Felodipine 5
Normalized name: felodipine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine 5 mg twice daily for 4 weeks, then increased to 10 mg twice daily for another 4 weeks, followed by open-label felodipine 5-15 mg twice daily for 1 year.
Study: 1981681
Drug: Hydrochlorothiazide 25
Normalized name: hydrochlorothiazide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 25 mg once daily for 4 weeks, then increased to 50 mg once daily for another 4 weeks.
Study: 7376786
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g GABA (single dose)
Study: 7376786
Drug: 18 g
Normalized name: flotufolastat F 18 gallium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 g GABA (daily for 4 days)
Study: 17000096
Drug: Bronchodilators (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bronchodilators (5 mg salbutamol plus 500 microg ipratropium bromide nebulisation)
Study: 17000096
Drug: Oxygen therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen therapy (without bronchodilators)
Study: 17000096
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of oxygen and bronchodilators
Study: 15087613
Drug: Alfentanil (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil (target concentration, 80 ng/ml)
Study: 9789907
Drug: Quetiapine fumarate
Normalized name: Quetiapine Fumarate
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine fumarate treatment
Study: 26435375
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy arm of the ACCORD trial
Study: 24780946
Drug: Hypolipidic diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypolipidic diet and phyto-supplement (group E)
Study: 22492367
Drug: Daily consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily consumption of hazelnuts, chocolate, and potato chips (∼1100 kJ/d) for 12 weeks
Study: 19195326
Drug: Elvitegravir/r (150/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elvitegravir/r (150/100 mg once daily) plus etravirine (200 mg twice daily)
Study: 12969695
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy (estradiol, 2 mg p.o., plus norethisterone acetate, 1 mg)
Study: 10596203
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anaesthesia with fentanyl and midazolam
Study: 6414682
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy program (specifics not provided)
Study: 3970673
Drug: Endarterectomized superficial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endarterectomized superficial femoral artery (ESFA) patch angioplasty
Study: 3970673
Drug: Vein patch
Normalized name: Sus scrofa vein preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vein patch
Study: 22993919
Drug: Hopaten acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hopaten acid (40 mg/kg per day)
Study: 22993919
Drug: Propofol-fentanyl total
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol-fentanyl total intravenous anesthesia (TIVA) without hopaten acid
Study: 20036427
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg tranylcypromine
Study: 20036427
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg tranylcypromine
Study: 17624978
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) plus referral to Gamblers Anonymous (GA)
Study: 10796061
Drug: Immediate Release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate Release (IR) formulation of indapamide (2.5 mg)
Study: 10796061
Drug: Sustained Release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained Release (SR) formulation of indapamide (1.5 mg)
Study: 10796061
Drug: Sustained Release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained Release (SR) formulation of indapamide (1.5 mg) after repeated administration
Study: 10796061
Drug: Immediate Release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate Release (IR) formulation of indapamide (2.5 mg) after repeated administration
Study: 8891006
Drug: 10% urea
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% urea ointment
Study: 1795202
Drug: Long-acting calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting calcium antagonists
Study: 31403596
Drug: Mind Over
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mind Over Matter: Healthy Bowels, Healthy Bladder (treatment group)
Study: 17710289
Drug: Dentifrice A
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dentifrice A (523 microgF/g)
Study: 17710289
Drug: Dentifrice B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dentifrice B (1,062 microgF/g)
Study: 17710289
Drug: Dentifrice C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dentifrice C (1,373 microgF/g)
Study: 12577455
Drug: Parenteral administration
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral administration of 30 g of alanyl‐glutamine dipeptide (Dipeptiven, Fresenius‐Kabi) from day +1 to day +14 or to discharge from hospital
Study: 12577455
Drug: Isolated control
Normalized name: ISOLATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isolated control group receiving isonitrogenous glutamine‐free amino acid solution from day +1 to day +14 or to discharge from hospital